| KNBIF Stock | | | USD 0.08 0.0003 0.39% |
Insider
Gregory Schultz is Chief Board of Kane Biotech
| Age | 73 |
| Phone | 204 453 1301 |
| Web | https://kanebiotech.com |
Kane Biotech Management Efficiency
The company has return on total asset
(ROA) of
(0.3915) % which means that it has lost $0.3915 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(5.968) %, meaning that it generated substantial loss on money invested by shareholders. Kane Biotech's management efficiency ratios could be used to measure how well Kane Biotech manages its routine affairs as well as how well it operates its assets and liabilities.
Kane Biotech has accumulated 1.12
M in total debt with debt to equity ratio
(D/E) of 7.12, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Kane Biotech has a current ratio of 0.66, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Kane Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Kane Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Kane Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Kane to invest in growth at high rates of return. When we think about Kane Biotech's use of debt, we should always consider it together with cash and equity.
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada. Kane Biotech is traded on OTC Exchange in the United States. Kane Biotech [KNBIF] is traded as part of a regulated electronic over-the-counter service offered by the NASD.
Management Performance
Kane Biotech Leadership Team
Elected by the shareholders, the Kane Biotech's board of directors comprises two types of representatives: Kane Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kane. The board's role is to monitor Kane Biotech's management team and ensure that shareholders' interests are well served. Kane Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kane Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kevin Cole, Pres Inc | |
| Wendy Nachtigall, Director Marketing | |
| Mark AhrensTownsend, President CEO | |
| Gregory Schultz, Chief Board | |
| Lorne Gorber, Investor Relations | |
| Marc Edwards, Interim CEO, Director | |
| Ray Dupuis, Chief Officer | |
| Nicole Sendey, Investor Adviser | |
| Lori Christofalos, VP Compliance | |
Kane Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Kane Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Kane OTC Stock
Kane Biotech financial ratios help investors to determine whether Kane OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kane with respect to the benefits of owning Kane Biotech security.